Riboxin 200 mg 50 tablets, film-coated

Indications for use in adults in combination therapy for ischemic heart disease, myocardial dystrophy, post-myocardial infarction, and arrhythmias caused by the use of cardiac glycosides.

Indicated for hepatitis, cirrhosis, fatty liver dystrophy caused by alcohol or medications, and uroporphyria.

Administer orally before meals.
The daily dose for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (0.2 g 3-4 times a day). In case of good tolerance, the dose is increased (on the 2nd-3rd day) to 1.2 g (0.4 g 3 times a day), if necessary, up to 2.4 g per day.
Duration of the course is from 4 weeks to 1.5-3 months.
In acute porphyria, the daily dose is 0.8 g (0.2 g 4 times a day). The medication is taken daily for 1-3 months.

Per 1 tablet:
Active ingredient: inosine - 200.0 mg
Excipients: microcrystalline cellulose (MCC-101) - 40.0 mg; sucrose - 40.0 mg; potato starch - 17.0 mg; povidone-K25 - 10.0 mg; sodium croscarmellose - 6.0 mg; magnesium stearate - 3.0 mg; purified water - 4.0 mg.
Coating composition: hypromellose - 5.5 mg; polysorbate-80 - 1.5 mg; titanium dioxide - 3.0 mg.

Round, biconvex tablets coated with a film, white or almost white in color. A cross-section reveals a core that is white or almost white. The presence of slight surface roughness is permissible.

Increased sensitivity to the drug, gout, hyperuricemia.
Pregnancy, lactation period.
Age under 18 years.
With caution:
Renal insufficiency.

Inosine should be prescribed with caution in cases of kidney function impairment. In the event of itching and skin hyperemia, inosine should be discontinued.

Allergic reactions may occur in the form of urticaria, skin itching, skin hyperemia (discontinuation of the medication is required).
Rarely, during treatment with the medication, an increase in blood uric acid concentration and exacerbation of gout may occur (with prolonged use).

Metabolic agent, ATP precursor; exerts anti-hypoxic, metabolic, and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, and prevents the consequences of intraoperative kidney ischemia. Directly participates in glucose metabolism and promotes the activation of metabolism under hypoxic conditions and in the absence of ATP. Activates the metabolism of pyruvic acid to ensure normal tissue respiration, as well as promotes the activation of xanthine dehydrogenase. Stimulates nucleotide synthesis, enhances the activity of certain enzymes in the Krebs cycle. By penetrating cells, it raises the energy level, positively affects metabolic processes in the myocardium - increases the strength of heart contractions and contributes to more complete relaxation of the myocardium in diastole, resulting in an increased stroke volume. Reduces platelet aggregation, activates tissue regeneration (especially of the myocardium and the mucous membrane of the gastrointestinal tract (GIT)).

Well absorbed in the gastrointestinal tract. Metabolized in the liver with the formation of glucuronic acid and subsequent oxidation. Excreted in small amounts by the kidneys.